What drugs does Aurobindo Pharma make?

Aurobindo Pharma has 448 FDA-approved drugs including PRASUGREL, EZETIMIBE AND SIMVASTATIN, CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE.

What therapeutic areas does Aurobindo Pharma focus on?

Aurobindo Pharma focuses primarily on Cardiovascular and Neurology and 1 other therapeutic areas.

← Back

Data updated: Sep 20, 2026

Aurobindo Pharma

Generics

Cardiovascular Neurology Infectious Disease

Aurobindo Pharma is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease. Key products include LAMIVUDINE; ZIDOVUDINE.

1968

Since

448

Drugs

Trials

New Drugs (2yr)

Modality:

5 Small Molecules

Aurobindo Pharma's Key Drugs

Aurobindo Pharma's core commercial portfolio centers on PRASUGREL, EZETIMIBE AND SIMVASTATIN, CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

PRASUGREL

Cardiovascular

Thrombotic Cardiovascular Events

P2Y12 Approved 2017

EZETIMIBE AND SIMVASTATIN

Metabolic

Atherosclerotic Vascular Disease

NPC1L1 Approved 2017

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

Gastrointestinal

Gastrointestinal Disorder

Approved 2020

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

Cardiovascular

Hypertension

Calcium channel Approved 2012

LO-ZUMANDIMINE

Women's Health

Premenstrual Dysphoric Disorder

Approved 2018

Aurobindo Pharma's Recent FDA Approvals

Aurobindo Pharma secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

DULOXETINE HYDROCHLORIDE NDA

2026-02-27

duloxetine hydrochloride

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

Aurobindo Pharma's Therapeutic Areas

Aurobindo Pharma's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 37%

44 drugs

Neurology 21%

25 drugs

Infectious Disease 20%

24 drugs

Dermatology 13%

15 drugs Phase 3: 1

Respiratory 9%

10 drugs Phase 3: 2

Aurobindo Pharma's Top Competitors

Aurobindo Pharma's closest competitors by therapeutic-area and drug-target overlap include LEDERLE, Pfizer, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LEDERLE big-pharma

Infectious Disease, Dermatology, Cardiovascular, Neurology, Respiratory

Pfizer big-pharma

Infectious Disease, Neurology, Dermatology

GE HEALTHCARE specialty

Neurology, Cardiovascular, Infectious Disease, Respiratory

Merck big-pharma

Infectious Disease, Cardiovascular, Respiratory

Baxter specialty

Infectious Disease, Cardiovascular, Dermatology